Note to users. If you're seeing this message, it means that your browser cannot find this page's style/presentation instructions -- or possibly that you are using a browser that does not support current Web standards. Find out more about why this message is appearing, and what you can do to make your experience of our site the best it can be.


Science 30 April 1999:
Vol. 284. no. 5415, pp. 808 - 812
DOI: 10.1126/science.284.5415.808

Reports

Effects of Angiogenesis Inhibitors on Multistage Carcinogenesis in Mice

Gabriele Bergers, 1 Kashi Javaherian, 2 Kin-Ming Lo, 3 Judah Folkman, 2 Douglas Hanahan 1*

Solid tumors depend on angiogenesis for their growth. In a transgenic mouse model of pancreatic islet cell carcinogenesis (RIP1-Tag2), an angiogenic switch occurs in premalignant lesions, and angiogenesis persists during progression to expansive solid tumors and invasive carcinomas. RIP1-Tag2 mice were treated so as to compare the effects of four angiogenesis inhibitors at three distinct stages of disease progression. AGM-1470, angiostatin, BB-94, and endostatin each produced distinct efficacy profiles in trials aimed at preventing the angiogenic switch in premalignant lesions, intervening in the rapid expansion of small tumors, or inducing the regression of large end-stage cancers. Thus, anti-angiogenic drugs may prove most efficacious when they are targeted to specific stages of cancer.

1 Department of Biochemistry and Biophysics and Hormone Research Institute, University of California, San Francisco, 513 Parnassus Ave, San Francisco, CA 94143-0534, USA.
2 Department of Surgery, Children's Hospital Medical Center and Harvard Medical School, 300 Longwood Avenue, Boston, MA 02115, USA.
3 Lexigen Pharmaceuticals, 125 Hartwell Avenue, Lexington, MA 02173, USA.
*   To whom correspondence should be addressed. E-mail: dh{at}biochem.ucsf.edu


Read the Full Text


THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES:
Matrix Metalloproteinases As Novel Biomarkers and Potential Therapeutic Targets in Human Cancer.
R. Roy, J. Yang, and M. A. Moses (2009)
J. Clin. Oncol. 27, 5287-5297
   Abstract »    Full Text »    PDF »
Angiostatin regulates the expression of antiangiogenic and proapoptotic pathways via targeted inhibition of mitochondrial proteins.
T.-Y. Lee, S. Muschal, E. A. Pravda, J. Folkman, A. Abdollahi, and K. Javaherian (2009)
Blood 114, 1987-1998
   Abstract »    Full Text »    PDF »
Proteolytic Processing Causes Extensive Heterogeneity of Tissue Matrilin Forms.
H. W. A. Ehlen, G. Sengle, A. R. Klatt, A. Talke, S. Muller, M. Paulsson, and R. Wagener (2009)
J. Biol. Chem. 284, 21545-21556
   Abstract »    Full Text »    PDF »
A Spontaneous Acinar Cell Carcinoma Model for Monitoring Progression of Pancreatic Lesions and Response to Treatment Through Noninvasive Bioluminescence Imaging.
N. Zhang, S. Lyons, E. Lim, and P. Lassota (2009)
Clin. Cancer Res. 15, 4915-4924
   Abstract »    Full Text »    PDF »
Cancer Prevention: From 1727 to Milestones of the Past 100 Years.
S. M. Lippman and E. T. Hawk (2009)
Cancer Res. 69, 5269-5284
   Abstract »    Full Text »    PDF »
Cancer Prevention Research: Back to the Future.
S. M. Lippman (2009)
Cancer Prevention Research 2, 503-513
   Full Text »    PDF »
Targeting Angiogenesis from Premalignancy to Metastases.
J. R. Grandis and A. Argiris (2009)
Cancer Prevention Research 2, 291-294
   Full Text »    PDF »
Effect of covalent antithrombin-heparin complex on developmental mechanisms in the lung.
N. Parmar, L. R. Berry, M. Post, and A. K. C. Chan (2009)
Am J Physiol Lung Cell Mol Physiol 296, L394-L403
   Abstract »    Full Text »    PDF »
Distinct functions for the catalytic and hemopexin domains of a Drosophila matrix metalloproteinase.
B. M. Glasheen, A. T. Kabra, and A. Page-McCaw (2009)
PNAS 106, 2659-2664
   Abstract »    Full Text »    PDF »
High-Dose Fenretinide in Oral Leukoplakia.
W. N. William Jr., J. J. Lee, S. M. Lippman, J. W. Martin, N. Chakravarti, H. T. Tran, A. L. Sabichi, E. S. Kim, L. Feng, R. Lotan, et al. (2009)
Cancer Prevention Research 2, 22-26
   Abstract »    Full Text »    PDF »
Differential effects of the vascular endothelial growth factor receptor inhibitor PTK787/ZK222584 on tumor angiogenesis and tumor lymphangiogenesis.
T. Schomber, A. Zumsteg, K. Strittmatter, I. Crnic, H. Antoniadis, A. Littlewood-Evans, J. Wood, and G. Christofori (2009)
Mol. Cancer Ther. 8, 55-63
   Abstract »    Full Text »    PDF »
Three-dimensional MR mapping of angiogenesis with {alpha}5{beta}1({alpha}{nu}{beta}3)-targeted theranostic nanoparticles in the MDA-MB-435 xenograft mouse model.
A. H. Schmieder, S. D. Caruthers, H. Zhang, T. A. Williams, J. D. Robertson, S. A. Wickline, and G. M. Lanza (2008)
FASEB J 22, 4179-4189
   Abstract »    Full Text »    PDF »
FoxM1B Transcriptionally Regulates Vascular Endothelial Growth Factor Expression and Promotes the Angiogenesis and Growth of Glioma Cells.
Y. Zhang, N. Zhang, B. Dai, M. Liu, R. Sawaya, K. Xie, and S. Huang (2008)
Cancer Res. 68, 8733-8742
   Abstract »    Full Text »    PDF »
Matrilysin (MMP-7) Is a Novel Broadly Expressed Tumor Antigen Recognized by Antigen-Specific T Cells.
Y. Yokoyama, F. Grunebach, S. M. Schmidt, A. Heine, M. Hantschel, S. Stevanovic, H.-G. Rammensee, and P. Brossart (2008)
Clin. Cancer Res. 14, 5503-5511
   Abstract »    Full Text »    PDF »
Minute dosages of {alpha}{nu}{beta}3-targeted fumagillin nanoparticles impair Vx-2 tumor angiogenesis and development in rabbits.
P. M. Winter, A. H. Schmieder, S. D. Caruthers, J. L. Keene, H. Zhang, S. A. Wickline, and G. M. Lanza (2008)
FASEB J 22, 2758-2767
   Abstract »    Full Text »    PDF »
BIBF 1120: Triple Angiokinase Inhibitor with Sustained Receptor Blockade and Good Antitumor Efficacy.
F. Hilberg, G. J. Roth, M. Krssak, S. Kautschitsch, W. Sommergruber, U. Tontsch-Grunt, P. Garin-Chesa, G. Bader, A. Zoephel, J. Quant, et al. (2008)
Cancer Res. 68, 4774-4782
   Abstract »    Full Text »    PDF »
Increased Metabolic Activity of Indolent Liver Metastases After Resection of a Primary Colorectal Tumor.
M. G.W. Scheer, T. H. Stollman, W. V. Vogel, O. C. Boerman, W. J.G. Oyen, and T. J.M. Ruers (2008)
J. Nucl. Med. 49, 887-891
   Abstract »    Full Text »    PDF »
Plasminogen activator inhibitor-1 inhibits prostate tumor growth through endothelial apoptosis.
S.-C. Chen, D. O. Henry, P. R. Reczek, and M. K.K. Wong (2008)
Mol. Cancer Ther. 7, 1227-1236
   Abstract »    Full Text »    PDF »
Interleukin-15/Interleukin-15R{alpha} Complexes Promote Destruction of Established Tumors by Reviving Tumor-Resident CD8+ T Cells.
M. Epardaud, K. G. Elpek, M. P. Rubinstein, A.-r. Yonekura, A. Bellemare-Pelletier, R. Bronson, J. A. Hamerman, A. W. Goldrath, and S. J. Turley (2008)
Cancer Res. 68, 2972-2983
   Abstract »    Full Text »    PDF »
Tumor Models for Efficacy Determination.
B. A Teicher (2008)
Am. Assoc. Cancer Res. Educ. Book 2008, 571-585
   Abstract »    Full Text »    PDF »
Linking Antibody Fc Domain to Endostatin Significantly Improves Endostatin Half-life and Efficacy.
T.-Y. Lee, R. M. Tjin Tham Sjin, S. Movahedi, B. Ahmed, E. A. Pravda, K.-M. Lo, S. D. Gillies, J. Folkman, and K. Javaherian (2008)
Clin. Cancer Res. 14, 1487-1493
   Abstract »    Full Text »    PDF »
Role of Bv8 in neutrophil-dependent angiogenesis in a transgenic model of cancer progression.
F. Shojaei, M. Singh, J. D. Thompson, and N. Ferrara (2008)
PNAS 105, 2640-2645
   Abstract »    Full Text »    PDF »
An Endothelial Cell Genetic Screen Identifies the GTPase Rem2 as a Suppressor of p19ARF Expression That Promotes Endothelial Cell Proliferation and Angiogenesis.
R. Bierings, M. Beato, and M. J. Edel (2008)
J. Biol. Chem. 283, 4408-4416
   Abstract »    Full Text »    PDF »
Mast cells are an essential hematopoietic component for polyp development.
E. Gounaris, S. E. Erdman, C. Restaino, M. F. Gurish, D. S. Friend, F. Gounari, D. M. Lee, G. Zhang, J. N. Glickman, K. Shin, et al. (2007)
PNAS 104, 19977-19982
   Abstract »    Full Text »    PDF »
Inhibitory effects of resistin-13-peptide on the proliferation, adhesion, and invasion of MDA-MB-231 in human breast carcinoma cells.
B. Pan, M.-H. Zhao, Z. Chen, L. Lu, Y. Wang, D.-W. Shi, and P.-Z. Han (2007)
Endocr. Relat. Cancer 14, 1063-1071
   Abstract »    Full Text »    PDF »
Meeting Report: Fifth Annual AACR Frontiers in Cancer Prevention Research.
A. Hoque, H. L. Parnes, M. E. Stefanek, J. V. Heymach, P. H. Brown, and S. M. Lippman (2007)
Cancer Res. 67, 8989-8993
   Abstract »    Full Text »    PDF »
Inhibition of Cysteine Cathepsin Protease Activity Enhances Chemotherapy Regimens by Decreasing Tumor Growth and Invasiveness in a Mouse Model of Multistage Cancer.
K. M. Bell-McGuinn, A. L. Garfall, M. Bogyo, D. Hanahan, and J. A. Joyce (2007)
Cancer Res. 67, 7378-7385
   Abstract »    Full Text »    PDF »
New drug development in digestive neuroendocrine tumors.
I Duran, R Salazar, O Casanovas, V Arrazubi, E Vilar, L. Siu, J Yao, and J Tabernero (2007)
Ann. Onc. 18, 1307-1313
   Abstract »    Full Text »    PDF »
MFG-E8/Lactadherin Promotes Tumor Growth in an Angiogenesis-Dependent Transgenic Mouse Model of Multistage Carcinogenesis.
M. Neutzner, T. Lopez, X. Feng, E. S. Bergmann-Leitner, W. W. Leitner, and M. C. Udey (2007)
Cancer Res. 67, 6777-6785
   Abstract »    Full Text »    PDF »
[Lys40(Ahx-DTPA-111In)NH2]-Exendin-4 Is a Highly Efficient Radiotherapeutic for Glucagon-Like Peptide-1 Receptor-Targeted Therapy for Insulinoma.
A. Wicki, D. Wild, D. Storch, C. Seemayer, M. Gotthardt, M. Behe, S. Kneifel, M. J. Mihatsch, J.-C. Reubi, H. R. Macke, et al. (2007)
Clin. Cancer Res. 13, 3696-3705
   Abstract »    Full Text »    PDF »
Macrophages Regulate the Angiogenic Switch in a Mouse Model of Breast Cancer.
E. Y. Lin, J.-F. Li, L. Gnatovskiy, Y. Deng, L. Zhu, D. A. Grzesik, H. Qian, X.-n. Xue, and J. W. Pollard (2006)
Cancer Res. 66, 11238-11246
   Abstract »    Full Text »    PDF »
Giving blood: a new role for CD40 in tumorigenesis.
S. Bergmann and P. P. Pandolfi (2006)
J. Exp. Med. 203, 2409-2412
   Abstract »    Full Text »    PDF »
Moderate antiangiogenic activity by local, transgenic expression of endostatin in Rip1Tag2 transgenic mice.
B. Schaffhauser, T. Veikkola, K. Strittmatter, H. Antoniadis, K. Alitalo, and G. Christofori (2006)
J. Leukoc. Biol. 80, 669-676
   Abstract »    Full Text »    PDF »
Tumor models for efficacy determination..
B. A. Teicher (2006)
Mol. Cancer Ther. 5, 2435-2443
   Abstract »    Full Text »    PDF »
Magnitude of Stromal Hemangiogenesis Correlates with Histologic Subtype of Non-Hodgkin's Lymphoma..
J. Ruan, E. Hyjek, P. Kermani, P. J. Christos, A. T. Hooper, M. Coleman, B. Hempstead, J. P. Leonard, A. Chadburn, and S. Rafii (2006)
Clin. Cancer Res. 12, 5622-5631
   Abstract »    Full Text »    PDF »
The use of targeted mouse models for preclinical testing of novel cancer therapeutics..
K. P. Olive and D. A. Tuveson (2006)
Clin. Cancer Res. 12, 5277-5287
   Abstract »    Full Text »    PDF »
Using genetically engineered mouse models of cancer to aid drug development: an industry perspective..
M. Singh and L. Johnson (2006)
Clin. Cancer Res. 12, 5312-5328
   Abstract »    Full Text »    PDF »
Angiogenesis in Atherogenesis.
J. Herrmann, L. O. Lerman, D. Mukhopadhyay, C. Napoli, and A. Lerman (2006)
Arterioscler Thromb Vasc Biol 26, 1948-1957
   Abstract »    Full Text »    PDF »
Infiltrating neutrophils mediate the initial angiogenic switch in a mouse model of multistage carcinogenesis.
H. Nozawa, C. Chiu, and D. Hanahan (2006)
PNAS 103, 12493-12498
   Abstract »    Full Text »    PDF »
Phase II Study of Recombinant Human Endostatin in Patients With Advanced Neuroendocrine Tumors.
M. H. Kulke, E. K. Bergsland, D. P. Ryan, P. C. Enzinger, T. J. Lynch, A. X. Zhu, J. A. Meyerhardt, J. V. Heymach, W. E. Fogler, C. Sidor, et al. (2006)
J. Clin. Oncol. 24, 3555-3561
   Abstract »    Full Text »    PDF »
Targeted gene disruption of methionine aminopeptidase 2 results in an embryonic gastrulation defect and endothelial cell growth arrest.
J.-R. J. Yeh, R. Ju, C. M. Brdlik, W. Zhang, Y. Zhang, M. E. Matyskiela, J. D. Shotwell, and C. M. Crews (2006)
PNAS 103, 10379-10384
   Abstract »    Full Text »    PDF »
BRCA1 Plays a Role in the Hypoxic Response by Regulating HIF-1{alpha} Stability and by Modulating Vascular Endothelial Growth Factor Expression.
H. J. Kang, H. J. Kim, J.-K. Rih, T. L. Mattson, K. W. Kim, C.-H. Cho, J. S. Isaacs, and I. Bae (2006)
J. Biol. Chem. 281, 13047-13056
   Abstract »    Full Text »    PDF »
Crosstalk between Extrinsic and Intrinsic Cell Death Pathways in Pancreatic Cancer: Synergistic Action of Estrogen Metabolite and Ligands of Death Receptor Family..
A. Basu, V. P. Castle, M. Bouziane, K. Bhalla, and S. Haldar (2006)
Cancer Res. 66, 4309-4318
   Abstract »    Full Text »    PDF »
Distinct tumor stage-specific inhibitory effects of 2-methoxyestradiol in a breast cancer mouse model associated with id-1 expression..
J.-I. Huh, A. Calvo, R. Charles, and J. E. Green (2006)
Cancer Res. 66, 3495-3503
   Abstract »    Full Text »    PDF »
Preclinical activity of ABT-869, a multitargeted receptor tyrosine kinase inhibitor..
D. H. Albert, P. Tapang, T. J. Magoc, L. J. Pease, D. R. Reuter, R.-Q. Wei, J. Li, J. Guo, P. F. Bousquet, N. S. Ghoreishi-Haack, et al. (2006)
Mol. Cancer Ther. 5, 995-1006
   Abstract »    Full Text »    PDF »
Inhibitory Effects of Lycopene on the Adhesion, Invasion, and Migration of SK-Hep1 Human Hepatoma Cells..
E.-S. Hwang and H. J. Lee (2006)
Experimental Biology and Medicine 231, 322-327
   Abstract »    Full Text »    PDF »
Treatment of pancreatic carcinoma by adenoviral mediated gene transfer of vasostatin in mice.
L Li, Y-Z Yuan, J Lu, L Xia, Y Zhu, Y-P Zhang, and M-M Qiao (2006)
Gut 55, 259-265
   Abstract »    Full Text »    PDF »
Impact of Vascular Endothelial Growth Factor-A Expression, Thrombospondin-2 Expression, and Microvessel Density on the Treatment Effect of Bevacizumab in Metastatic Colorectal Cancer.
A. M. Jubb, H. I. Hurwitz, W. Bai, E. B. Holmgren, P. Tobin, A. S. Guerrero, F. Kabbinavar, S. N. Holden, W. F. Novotny, G. D. Frantz, et al. (2006)
J. Clin. Oncol. 24, 217-227
   Abstract »    Full Text »    PDF »
Phase I Trial of the Oral Antiangiogenesis Agent AG-013736 in Patients With Advanced Solid Tumors: Pharmacokinetic and Clinical Results.
H. S. Rugo, R. S. Herbst, G. Liu, J. W. Park, M. S. Kies, H. M. Steinfeldt, Y. K. Pithavala, S. D. Reich, J. L. Freddo, and G. Wilding (2005)
J. Clin. Oncol. 23, 5474-5483
   Abstract »    Full Text »    PDF »
Measurement of Matrix Metalloproteinases in Serum of Patients with Melanoma: Snarled in Technical Pitfalls.
S. Zucker and J. Cao (2005)
Clin. Cancer Res. 11, 5069-5070
   Full Text »    PDF »
Specific Interference of Urokinase-type Plasminogen Activator Receptor and Matrix Metalloproteinase-9 Gene Expression Induced by Double-stranded RNA Results in Decreased Invasion, Tumor Growth, and Angiogenesis in Gliomas.
S. S. Lakka, C. S. Gondi, D. H. Dinh, W. C. Olivero, M. Gujrati, V. H. Rao, C. Sioka, and J. S. Rao (2005)
J. Biol. Chem. 280, 21882-21892
   Abstract »    Full Text »    PDF »
A 27-Amino-Acid Synthetic Peptide Corresponding to the NH2-Terminal Zinc-Binding Domain of Endostatin Is Responsible for Its Antitumor Activity.
R. M. Tjin Tham Sjin, R. Satchi-Fainaro, A. E. Birsner, V.M. S. Ramanujam, J. Folkman, and K. Javaherian (2005)
Cancer Res. 65, 3656-3663
   Abstract »    Full Text »    PDF »
Learning from Our Mistakes: The Translation of MMPIs from Laboratory to Clinical Trial.
B. Fingleton (2005)
Am. Assoc. Cancer Res. Educ. Book 2005, 30-32
   Full Text »    PDF »
Challenges in Translating Antiangiogenic Therapy from Bench to Bedside.
L. M. Ellis (2005)
Am. Assoc. Cancer Res. Educ. Book 2005, 74-77
   Full Text »    PDF »
Antiangiogenic Concentrations of Paclitaxel Induce an Increase in Microtubule Dynamics in Endothelial Cells but Not in Cancer Cells.
E. Pasquier, S. Honore, B. Pourroy, M. A. Jordan, M. Lehmann, C. Briand, and D. Braguer (2005)
Cancer Res. 65, 2433-2440
   Abstract »    Full Text »    PDF »
Combination of Antiangiogenic Therapy With Other Anticancer Therapies: Results, Challenges, and Open Questions.
G. Gasparini, R. Longo, M. Fanelli, and B. A. Teicher (2005)
J. Clin. Oncol. 23, 1295-1311
   Abstract »    Full Text »    PDF »
A Multitargeted, Metronomic, and Maximum-Tolerated Dose "Chemo-Switch" Regimen is Antiangiogenic, Producing Objective Responses and Survival Benefit in a Mouse Model of Cancer.
K. Pietras and D. Hanahan (2005)
J. Clin. Oncol. 23, 939-952
   Abstract »    Full Text »    PDF »
50 Years of Preclinical Anticancer Drug Screening: Empirical to Target-Driven Approaches.
M. Suggitt and M. C. Bibby (2005)
Clin. Cancer Res. 11, 971-981
   Abstract »    Full Text »    PDF »
Therapy of Hematogenous Melanoma Brain Metastases with Endostatin.
M. Kirsch, P. Weigel, T. Pinzer, R. S. Carroll, P. McL. Black, H.-K. Schackert, and G. Schackert (2005)
Clin. Cancer Res. 11, 1259-1267
   Abstract »    Full Text »    PDF »
Regulator of G-protein signaling-5 induction in pericytes coincides with active vessel remodeling during neovascularization.
M. Berger, G. Bergers, B. Arnold, G. J. Hammerling, and R. Ganss (2005)
Blood 105, 1094-1101
   Abstract »    Full Text »    PDF »
Characterization of a First-Pass Gradient-Echo Spin-Echo Method to Predict Brain Tumor Grade and Angiogenesis.
K. M. Schmainda, S. D. Rand, A. M. Joseph, R. Lund, B. D. Ward, A. P. Pathak, J. L. Ulmer, M. A. Baddrudoja, and H. G. J. Krouwer (2004)
AJNR Am. J. Neuroradiol. 25, 1524-1532
   Abstract »    Full Text »    PDF »
Expression of the Type-1 Repeats of Thrombospondin-1 Inhibits Tumor Growth Through Activation of Transforming Growth Factor-{beta}.
K. O. Yee, M. Streit, T. Hawighorst, M. Detmar, and J. Lawler (2004)
Am. J. Pathol. 165, 541-552
   Abstract »    Full Text »    PDF »
Gene Therapy with Secretory Leukoprotease Inhibitor Promoter-Controlled Replication-Competent Adenovirus for Non-Small Cell Lung Cancer.
M. Maemondo, Y. Saijo, K. Narumi, T. Kikuchi, K. Usui, R. Tazawa, K. Matsumoto, T. Nakamura, K. Sasaki, M. Takahashi, et al. (2004)
Cancer Res. 64, 4611-4620
   Abstract »    Full Text »    PDF »
Inhibition of Vascular Endothelial Growth Factor (VEGF) Signaling in Cancer Causes Loss of Endothelial Fenestrations, Regression of Tumor Vessels, and Appearance of Basement Membrane Ghosts.
T. Inai, M. Mancuso, H. Hashizume, F. Baffert, A. Haskell, P. Baluk, D. D. Hu-Lowe, D. R. Shalinsky, G. Thurston, G. D. Yancopoulos, et al. (2004)
Am. J. Pathol. 165, 35-52
   Abstract »    Full Text »    PDF »
Retinoic acid controls blood vessel formation by modulating endothelial and mural cell interaction via suppression of Tie2 signaling in vascular progenitor cells.
Y. Suzuki, Y. Komi, H. Ashino, J. Yamashita, J. Inoue, A. Yoshiki, A. Eichmann, H. Amanuma, and S. Kojima (2004)
Blood 104, 166-169
   Abstract »    Full Text »    PDF »
Mucosal angiogenesis regulation by CXCR4 and its ligand CXCL12 expressed by human intestinal microvascular endothelial cells.
J. Heidemann, H. Ogawa, P. Rafiee, N. Lugering, C. Maaser, W. Domschke, D. G. Binion, and M. B. Dwinell (2004)
Am J Physiol Gastrointest Liver Physiol 286, G1059-G1068
   Abstract »    Full Text »    PDF »
Rationale for Biomarkers and Surrogate End Points in Mechanism-Driven Oncology Drug Development.
J. W. Park, R. S. Kerbel, G. J. Kelloff, J. C. Barrett, B. A. Chabner, D. R. Parkinson, J. Peck, R. W. Ruddon, C. C. Sigman, and D. J. Slamon (2004)
Clin. Cancer Res. 10, 3885-3896
   Full Text »    PDF »
E-selectin is required for the antiangiogenic activity of endostatin.
Y. Yu, K. S. Moulton, M. K. Khan, S. Vineberg, E. Boye, V. M. Davis, P. E. O'Donnell, J. Bischoff, and D. S. Milstone (2004)
PNAS 101, 8005-8010
   Abstract »    Full Text »    PDF »
Endothelial Cell Surface ATP Synthase-Triggered Caspase-Apoptotic Pathway Is Essential for K1-5-Induced Antiangiogenesis.
N. Veitonmaki, R. Cao, L.-H. Wu, T. L. Moser, B. Li, S. V. Pizzo, B. Zhivotovsky, and Y. Cao (2004)
Cancer Res. 64, 3679-3686
   Abstract »    Full Text »    PDF »
Inhibition of Orthotopic Human Bladder Tumor Growth by Lentiviral Gene Transfer of Endostatin.
E. Kikuchi, S. Menendez, M. Ohori, C. Cordon-Cardo, N. Kasahara, and B. H. Bochner (2004)
Clin. Cancer Res. 10, 1835-1842
   Abstract »    Full Text »    PDF »
The Tumor Suppressor p53 Inhibits Net, an Effector of Ras/Extracellular Signal-Regulated Kinase Signaling.
K. Nakade, H. Zheng, G. Ganguli, G. Buchwalter, C. Gross, and B. Wasylyk (2004)
Mol. Cell. Biol. 24, 1132-1142
   Abstract »    Full Text »    PDF »
Antiangiogenic and Antitumor Efficacy of EphA2 Receptor Antagonist.
P. Dobrzanski, K. Hunter, S. Jones-Bolin, H. Chang, C. Robinson, S. Pritchard, H. Zhao, and B. Ruggeri (2004)
Cancer Res. 64, 910-919
   Abstract »    Full Text »    PDF »
TIMP-1 Alters Susceptibility to Carcinogenesis.
J.-S. Rhee, R. Diaz, L. Korets, J. G. Hodgson, and L. M. Coussens (2004)
Cancer Res. 64, 952-961
   Abstract »    Full Text »    PDF »
Cell Surface-Dependent Generation of Angiostatin4.5.
H. Wang, R. Schultz, J. Hong, D. L. Cundiff, K. Jiang, and G. A. Soff (2004)
Cancer Res. 64, 162-168
   Abstract »    Full Text »    PDF »
Combined Therapy with Direct and Indirect Angiogenesis Inhibition Results in Enhanced Antiangiogenic and Antitumor Effects.
A. Abdollahi, K. E. Lipson, A. Sckell, H. Zieher, F. Klenke, D. Poerschke, A. Roth, X. Han, M. Krix, M. Bischof, et al. (2003)
Cancer Res. 63, 8890-8898
   Abstract »    Full Text »    PDF »
Inhibition of Kaposi's Sarcoma in Vivo by Fenretinide.
N. Ferrari, M. Morini, U. Pfeffer, S. Minghelli, D. M. Noonan, and A. Albini (2003)
Clin. Cancer Res. 9, 6020-6029
   Abstract »    Full Text »    PDF »
Tumor Suppression by a Rationally Designed Reversible Inhibitor of Methionine Aminopeptidase-2.
J. Wang, G. S. Sheppard, P. Lou, M. Kawai, N. BaMaung, S. A. Erickson, L. Tucker-Garcia, C. Park, J. Bouska, Y.-C. Wang, et al. (2003)
Cancer Res. 63, 7861-7869
   Abstract »    Full Text »    PDF »
The Generation of a Conditional Reporter That Enables Bioluminescence Imaging of Cre/loxP-Dependent Tumorigenesis in Mice.
S. K. Lyons, R. Meuwissen, P. Krimpenfort, and A. Berns (2003)
Cancer Res. 63, 7042-7046
   Abstract »    Full Text »    PDF »
Angiogenesis in Endocrine Tumors.
H. E. Turner, A. L. Harris, S. Melmed, and J. A. H. Wass (2003)
Endocr. Rev. 24, 600-632
   Abstract »    Full Text »    PDF »
Dual Stromelysin-3 Function during Natural Mouse Mammary Tumor Virus-ras Tumor Progression.
K. L. Andarawewa, A. Boulay, R. Masson, C. Mathelin, I. Stoll, C. Tomasetto, M.-P. Chenard, M. Gintz, J.-P. Bellocq, and M.-C. Rio (2003)
Cancer Res. 63, 5844-5849
   Abstract »    Full Text »    PDF »
The transcription factor Net regulates the angiogenic switch.
H. Zheng, C. Wasylyk, A. Ayadi, J. Abecassis, J. A Schalken, H. Rogatsch, N. Wernert, S.-M. Maira, M.-C. Multon, and B. Wasylyk (2003)
Genes & Dev. 17, 2283-2297
   Abstract »    Full Text »    PDF »
Stage-Dependent Expression of an Angiogenic Agent and Vascular Organization in Experimental Skin Tumor Development.
V. Nayha, J. Laitakari, and F. Stenback (2003)
Toxicol Pathol 31, 539-548
   Abstract »    PDF »
Inhibition of Angiogenesis and Angiogenesis-dependent Tumor Growth by the Cryptic Kringle Fragments of Human Apolipoprotein(a).
J.-S. Kim, J.-H. Chang, H.-K. Yu, J.-H. Ahn, J.-S. Yum, S.-K. Lee, K.-H. Jung, D.-H. Park, Y. Yoon, S.-M. Byun, et al. (2003)
J. Biol. Chem. 278, 29000-29008
   Abstract »    Full Text »    PDF »
Building a better Trap.
J. D. Hood and D. A. Cheresh (2003)
PNAS 100, 8624-8625
   Full Text »    PDF »
Corneal Transduction to Inhibit Angiogenesis and Graft Failure.
R. C. Murthy, T. J. McFarland, J. Yoken, S. Chen, C. Barone, D. Burke, Y. Zhang, B. Appukuttan, and J. T. Stout (2003)
Invest. Ophthalmol. Vis. Sci. 44, 1837-1842
   Abstract »    Full Text »    PDF »
Inhibition of rat corneal angiogenesis by a nuclease-resistant RNA aptamer specific for angiopoietin-2.
R. R. White, S. Shan, C. P. Rusconi, G. Shetty, M. W. Dewhirst, C. D. Kontos, and B. A. Sullenger (2003)
PNAS 100, 5028-5033
   Abstract »    Full Text »    PDF »
Inhibition of plaque neovascularization reduces macrophage accumulation and progression of advanced atherosclerosis.
K. S. Moulton, K. Vakili, D. Zurakowski, M. Soliman, C. Butterfield, E. Sylvin, K.-M. Lo, S. Gillies, K. Javaherian, and J. Folkman (2003)
PNAS 100, 4736-4741
   Abstract »    Full Text »    PDF »
Molecular Therapeutics: Is One Promiscuous Drug against Multiple Targets Better than Combinations of Molecule-specific Drugs?.
C. L. Arteaga (2003)
Clin. Cancer Res. 9, 1231-1232
   Full Text »    PDF »
Anti-angiogenic Activity of the Recombinant Kringle Domain of Urokinase and Its Specific Entry into Endothelial Cells.
K. S. Kim, Y.-K. Hong, Y. A. Joe, Y. Lee, J.-Y. Shin, H.-E. Park, I.-H. Lee, S.-Y. Lee, D.-K. Kang, S.-I. Chang, et al. (2003)
J. Biol. Chem. 278, 11449-11456
   Abstract »    Full Text »    PDF »
Focal Adhesion Kinase Is Required for Blood Vessel Morphogenesis.
D. Ilic, B. Kovacic, S. McDonagh, F. Jin, C. Baumbusch, D. G. Gardner, and C. H. Damsky (2003)
Circ. Res. 92, 300-307
   Abstract »    Full Text »    PDF »
Increased collagenase activity in macrophages from bronchial lavage as a diagnostic marker of non-small cell lung cancer.
Y Hakoda, Y Ito, A Nagate, K Minemura, K Utsumi, M Aoshima, and K Ohyashiki (2003)
Thorax 58, 122-126
   Abstract »    Full Text »    PDF »
Antitumor Activity of the 16-kDa Prolactin Fragment in Prostate Cancer.
J. Kim, W. Luo, D.-T. Chen, K. Earley, J. Tunstead, L.-Y. Yu-Lee, and S.-H. Lin (2003)
Cancer Res. 63, 386-393
   Abstract »    Full Text »    PDF »
Prevention of leptin binding to its receptor suppresses rat leukemic cell growth by inhibiting angiogenesis.
P. O. Iversen, C. A. Drevon, and J. E. Reseland (2002)
Blood 100, 4123-4128
   Abstract »    Full Text »    PDF »
New functional roles for non-collagenous domains of basement membrane collagens.
N. Ortega and Z. Werb (2002)
J. Cell Sci. 115, 4201-4214
   Abstract »    Full Text »    PDF »
Safety and Pharmacokinetic Effects of TNP-470, an Angiogenesis Inhibitor, Combined With Paclitaxel in Patients With Solid Tumors: Evidence for Activity in Non-Small-Cell Lung Cancer.
R. S. Herbst, T. L. Madden, H. T. Tran, G. R. Blumenschein Jr, C. A. Meyers, L. F. Seabrooke, F. R. Khuri, V. K. Puduvalli, V. Allgood, H. A. Fritsche Jr, et al. (2002)
J. Clin. Oncol. 20, 4440-4447
   Abstract »    Full Text »    PDF »
Laminin Modulates Morphogenic Properties of the Collagen XVIII Endostatin Domain.
K. Javaherian, S. Y. Park, W. F. Pickl, K. R. LaMontagne, R. T. T. Sjin, S. Gillies, and K.-M. Lo (2002)
J. Biol. Chem. 277, 45211-45218
   Abstract »    Full Text »    PDF »
Vascular Permeability Factor/Vascular Endothelial Growth Factor: A Critical Cytokine in Tumor Angiogenesis and a Potential Target for Diagnosis and Therapy.
H. F. Dvorak (2002)
J. Clin. Oncol. 20, 4368-4380
   Abstract »    Full Text »    PDF »



To Advertise     Find Products


Science. ISSN 0036-8075 (print), 1095-9203 (online)